Inogen (INGN) investor relations material

Leadership and organizational changes

• New CFO brings 25 years of MedTech experience, including leadership roles at Hillrom and Baxter, with a focus on operational and growth initiatives.

• Recent hires include a Chief Marketing Officer and VP of US B2B Sales, reflecting a strategic realignment to accelerate growth and innovation.

• Expansion of leadership aims to support transformation from a single-product company to a broader respiratory care platform.

Product innovation and market expansion

• Launched Voxi 5 stationary concentrator, receiving strong feedback and expanding portfolio sales in both B2B and DTC channels.

• Progressing with regulatory approval to enter the Chinese market through a partnership, targeting a large COPD population.

• Simeox airway clearance device is on the market in Europe, with US clinical trials underway to secure reimbursement and expand TAM by $500 million.

• Entered the CPAP mask market with Aurora, focusing on new patient setups in a $400 million segment, leveraging existing sales and physician networks.

• Enhanced connectivity in POCs, offering benefits for patients, physicians, and HMEs, and building an ecosystem to drive loyalty and preference.

Channel performance and business dynamics

• B2B channel growth is offsetting headwinds in DTC rental and consumer sales, as more patients receive POCs directly from HMEs.

• DTC channel is being refined with new products and targeted marketing, aiming for profitable sales and leveraging opportunities beyond POCs.

• B2B market still has room for growth, with 40% of new patients receiving tanks, and innovation expected to drive future replacement demand.